• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 9th February 2011

The Spanish Medicines Market Today

Spending by Spain’s National Health Service (NHS) on pharmaceuticals was €12.1 billion in 2010. Its market for prescription medicines is among the slowest growing in Europe, expanding by only 1% for the 12 months to September 2010 – half of…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
JorgePhoto16-9-11

Spending by Spain’s National Health Service (NHS) on pharmaceuticals was €12.1 billion in 2010. Its market for prescription medicines is among the slowest growing in Europe, expanding by only 1% for the 12 months to September 2010 – half of the average of 2% for the five largest European markets.

Jorge Mestre-Ferrandiz Dr. Mestre-Ferrandiz

 

Spending by Spain’s National Health Service (NHS) on pharmaceuticals was €12.1 billion in 2010. Its market for prescription medicines is among the slowest growing in Europe, expanding by only 1% for the 12 months to September 2010 – half of the average of 2% for the five largest European markets. Reimbursement over the same period grew 2.3%, above Italy’s -1.2%, but well below France at 3.3%, the UK at 4.4% and Germany at 4.6%. For the 12 months preceding September 2010, reference priced generics accounted for 23.5% of the Spanish market by value, and 38.2% by volume. The penetration of generics in Spain, however, is low for Europe – about 12% by volume compared to 65% for the UK, for example. The past decade has been a time of major change in Spain’s medicines market, with key events occurring in 2002, 2004, 2006 and 2010.

  • In 2002, important responsibilities for health care were devolved to Spain’s autonomous regions. Although market authorisation, pricing and reimbursement for medicines still are decided at national level, regions have been implementing their own policies intended to affect demand and shape the market.
  • The change of government in 2004 meant an end to the ‘Stability Pact’ with the industry and the consideration of an array of other measures meant to control spending on medicines, included in the 2004 Strategic Pharmaceutical Plan.
  • In 2006, the new Medicines Act was approved, which was (at least partially) based on the 2004 Strategic Plan. The Act introduced a new reference pricing system, replacing the system introduced in 2003, as well as formalising procedures and requirements for reimbursement based on a calculus of need, therapeutic value/utility and ‘degree of innovation’.

In 2010, the reference pricing system again was changed and additional price cuts and rebates requirements were imposed.

  • Under the new reference pricing system, the level used to determine price is the least expensive daily treatment cost, based on defined daily dose (DDD). Manufacturers with products whose prices exceed the reference price by more than 30% may either cut prices immediately to the reference level or gradually reduce prices, but not by more than 50% a year. The reference price must be met in two years or the product no longer will be eligible for reimbursement.
  • Prices will be reduced by 30% (up from 20%) for reimbursed ambulatory and hospital diagnostic products marketed for over ten years (or eleven years if a new indication has been added), but for which no generic product is marketed in Spain (and so not part of the reference pricing system). This applies only if a cheaper generic or biosimilar is marketed in the EU15; final retail prices cannot be below €1.56. Generic versions in inactive reference price groups are included for the first time.
  • In May 2010, new price cuts were imposed on all reference priced generics, ranging from 0%-30% depending on the difference between the generic’s current price and the reference price. Exempted are medicines whose retail price is less than €3.12. Expected savings from these cuts are €169m.
  • In June 2010, new rebates were announced affecting only patented medicines reimbursed under the NHS. For all reimbursed medicines not in a reference price group, whether for ambulatory or hospital use, the rebate is 7.5% of the sales to the NHS. Orphan medicines are subject to a 4% rebate. Rebates apply to all parts of the medicine supply chain – manufacturers, wholesalers and pharmacies — each with its own margin. Expected savings from rebates are €700m from manufacturers and €350m from wholesalers and pharmacists.
  • In September 2010, the pharmaceutical industry met with the Prime Minister and is requesting the development of a strategic plan. The intent is to create a continuing platform for dialogue between the two parties and ensure some measure of stability in the market environment.

The role of Spain’s autonomous regions has been focused on affecting demand. For example, some regions have established agencies to evaluate therapeutic utility as a basis for creating prescribing guidelines. Serious questions have been raised about the quality of the evaluations and the appropriateness of the consequent guidelines, particularly because both financial and non-financial incentives have appeared to encourage physicians to follow the guidelines.

Other demand-side initiatives include, for example, regional reference pricing systems, binding only when prescription is by active ingredient; increasing generic prescribing; regional tendering; and creating regional catalogues that prioritise reimbursed medicines. Some such efforts, the catalogues, for example, appear to exceed regional authority and are being reviewed by the Department of Health.

Not all regions are equally active, of course, and they vary in the measures taken. For example, Andalusia, Catalonia and the Basque Country have taken the lead in pharmacoeconomic evaluations; Andalusia, the Canaries, Castilla-La Mancha, Castilla y Leon and Valencia have imposed regional reference prices; and Navarra, Extremadura, Catalonia and, soon, La Rioja attempt to shape prescribing and encourage greater use of generics.

For more information, please contact Dr. Jorge Mestre-Ferrandiz at OHE.

  • Health Technology Assessment…
  • Pricing and Reimbursement

Related News

  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
Danzon_Patricia_1305 (1)
  • News
  • June 2020

Victor R. Fuchs Award for 2020 Goes to Patricia Danzon

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!